Latest Breaking News On - Adult respiratory syncytial virus - Page 4 : comparemela.com

US FDA Approves GSK s AREXVY, the World s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

US FDA Approves GSK s AREXVY, the World s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofUnited kingdom generalCamilla campbellJohn kennedyKathleen quinnJosh williamsJeff mclaughlinNick stoneJames dodwellTony woodSimon mooreTim foleyMick readeySteph mountifield

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofUnited kingdom generalJohn kennedyKathleen quinnTony woodCamilla campbellSimon mooreNick stoneJames dodwellJosh williamsTim foleyMick readeySteph mountifieldJeff mclaughlin

GSK RSV older adult vaccine candidate publishes in New England Journal of Medicine

GSK RSV older adult vaccine candidate publishes in New England Journal of Medicine

Tony woodDrug administration vaccinesProducts advisory committeeNew england journalChief scientific officerVaccine clinical trials unitInstituto de investigaciSanitaria de santiagoDrug administrationRelated biological products advisory committeeBiologics license applicationAdult respiratory syncytial virus

Landmark New England Journal of Medicine publication reinforces potential of GSK s respiratory syncytial virus older adult vaccine candidate

GSK plc (LSE/NYSE: GSK) today announced the publication of positive phase III trial results for its respiratory syncytial virus (RSV) older adult vaccine candidate in the New England Journal of Medicine. The publication summarises the pivotal efficacy data (previously presented at IDWeek 2022), showing the vaccine .

Tony woodCompany annual report on formAntigenics incDrug administration vaccinesAgenus incProducts advisory committeeNew england journalChief scientific officerVaccine clinical trials unitInstituto de investigaciSanitaria de santiagoDrug administrationRelated biological products advisory committeeBiologics license applicationAdult respiratory syncytial virusAnnual report

GSK s Respiratory Syncytial Virus Older Adult Vaccine Candidate Gets FDA s Priority Review

LONDON (dpa-AFX) - British biopharma company GSK plc (GSK, GSK.L) announced Wednesday that the US Food and Drug Administration has accepted a Biologics License Application or BLA and granted Priority

United kingdomCity ofDrug administrationBiologics license applicationPriority reviewPrescription drug user fee actAdult respiratory syncytial virus